Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit - Akari Therapeutics (NASDAQ:AKTX)
BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory